José M. Viéitez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
José M. Viéitez has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Manuel Valladares-Ayerbes
Medical Oncology Department, Hospital Universitario Virgen del Rocio (HUVR), Institute of Biomedicine of Seville (IBiS), Seville, Spain
2 shared publications A. Lloansí Vila
Medical Oncology Department, Amgen S.A., Barcelona, Spain
1 shared publicationA. Salud Salvia
Medical Oncology Department, Hospital Arnau de Vilanova, Lleida, Spain
1 shared publicationAlfredo Falcone
1 shared publication- Beatriz García Paredes
Medical Oncology Department, Clínico San Carlos Hospital, Madrid, Spain
1 shared publication C. Guillén
1 shared publication
Latest Publications
- Open Access
- 14 October 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 177, 154-163
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
- 14 October 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 177, 154-163
Open AccessA randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
- Open Access
- 23 October 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_8) , viii183
First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study
Background: Tumour-tissue biopsy testing is the standard of care (SOC) to assess RAS mutation in mCRC pts. However, the analysis of circulating cell-free DNA (cfDNA) has the added advantage of being able to evidence genetic tumour heterogeneity. We explored the correlation of the RAS mutational status assessed in plasma samples with first-line (1L) treatment outcomes in SOC RAS wild type (wt) mCRC pts.
- 23 October 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_8) , viii183
Open AccessFirst-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study
Background: Tumour-tissue biopsy testing is the standard of care (SOC) to assess RAS mutation in mCRC pts. However, the analysis of circulating cell-free DNA (cfDNA) has the added advantage of being able to evidence genetic tumour heterogeneity. We explored the correlation of the RAS mutational status assessed in plasma samples with first-line (1L) treatment outcomes in SOC RAS wild type (wt) mCRC pts.